Replies to post #225812 on Biotech Values

[dewophile]

RVNC

There is nothing in the earnings PR about the biosimilar. Any update from the call - I wasn't able to catch it live - it must have come up at least in the Q&A
TIA

[DewDiligence]

RVNC 3Q19 results—pro-forma cash=$214M*:

https://investors.revance.com/news-releases/news-release-details/revance-completes-enrollment-aspen-1-phase-3-pivotal-trial

The BLA will be submitted during November, according to the PR.

Guidance for 2019 operating cash burn remains unchanged at $148-158M.

*Including $5M payment from Mylan, which has not yet been received.